Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 13/20 | 0.61 |
| ▸ | GNAI3 | P08754 | 12/20 | 0.56 |
| ▸ | GNAI1 | P63096 | 12/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9388213 | 1.00 | GNAO1 (0.61) | GNAO1GNAI3GNAI1CYP1A2EPHX1 | |
| SCHEMBL9385204 | 1.00 | GNAO1 (0.61) | GNAO1GNAI3GNAI1CYP1A2EPHX1 | |
| SCHEMBL9389331 | 1.00 | GNAO1 (0.61) | GNAO1GNAI3GNAI1CYP1A2EPHX1 | |
| SCHEMBL9383358 | 1.00 | GNAO1 (0.61) | GNAO1GNAI3GNAI1CYP1A2EPHX1 | |
| SCHEMBL7345197 | 1.00 | GNAO1 (0.61) | GNAO1GNAI3GNAI1CYP1A2EPHX1 | |
| SCHEMBL9384220 | 1.00 | GNAO1 (0.61) | GNAO1GNAI3GNAI1CYP1A2EPHX1 | |
| SCHEMBL9388856 | 1.00 | GNAO1 (0.61) | GNAO1GNAI3GNAI1CYP1A2EPHX1 | |
| Hydrochloric Acid SCHEMBL26090986 | 0.98 | GNAO1 (0.64) | GNAO1GNAI3GNAI1CYP1A2EPHX1 | |
| SCHEMBL1368752 | 0.98 | GNAO1 (0.58) | GNAO1GNAI3GNAI1CYP1A2EPHX1 | |
| Hydrochloric Acid SCHEMBL7645440 | 0.95 | GNAO1 (0.61) | GNAO1GNAI3GNAI1CYP1A2ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208411-B2 | Compositions and methods for treating parasitic diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200347050-A1 | TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-11-05 | — | — | US | disclosed |
| US-20200291030-A1 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-09-17 | — | — | US | disclosed |
| US-9975858-B2 | Benzimidazole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9802922-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170198006-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170129876-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2017-05-11 | — | — | US | disclosed |
| US-9409122-B2 | Gas capture process | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2016-08-09 | — | — | US | disclosed |
| US-20140127103-A1 | GAS CAPTURE PROCESS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2014-05-08 | — | — | US | disclosed |
| US-20070117847-A1 | N-(3-(4-Substituted-1-piperiding1)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | CHAMBERS MARK S | 2007-05-24 | — | — | US | disclosed |
| US-20020094989-A1 | Pyrrolidine modulators of CCR5 chemokine receptor activity | HALE JEFFREY J (US) | 2002-07-18 | — | — | US | disclosed |
| EP-1173170-A4 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2002-05-29 | — | — | EP | disclosed |
| EP-1192133-A1 | N-CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2002-04-03 | — | — | EP | disclosed |
| US-6358979-B1 | FOR THERAPY AND PROPHYLAXIS OF ASTHMA, ALLERGIC RHINITIS, DERMATITIS, CONJUNCTIVITIS, ATHEROSCLEROSIS OR RHEUMATOID ARTHRITIS, INFECTION BY HIV, TREATING INFECTION BY HIV, DELAYING OF THE ONSET OF AIDS | MERCK & CO., INC. | 2002-03-19 | — | — | US | disclosed |
| EP-1173170-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2002-01-23 | — | — | EP | disclosed |
| US-6265434-B1 | ANTIINFLAMMATORY AGENTS | MERCK & CO., INC. | 2001-07-24 | — | — | US | disclosed |
| WO-2000076972-A1 | N-CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000076514-A1 | CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000059503-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-10-12 | — | — | WO | disclosed |
| EP-0604494-A1 | 5-HT 4? RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291030-A1 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES | LIPA, LSS, LIPC | GNAO1 2827/4885GNAI3 2396/4885GNAI1 2505/4885 |
| US-11208411-B2 | Compositions and methods for treating parasitic diseases | LIPA, LSS, LIPC | GNAO1 2827/4885GNAI3 2396/4885GNAI1 2505/4885 |
| US-20170198006-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | GNAO1 2511/4885GNAI3 945/4885GNAI1 748/4885 |
| US-20070117847-A1 | N-(3-(4-Substituted-1-piperiding1)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | TACR2, KCNK3, KCNH3 | GNAO1 981/4885GNAI3 1362/4885GNAI1 1562/4885 |
| US-20020094989-A1 | Pyrrolidine modulators of CCR5 chemokine receptor activity | CCR5, CCR1, CXCR1 | GNAO1 943/4885GNAI3 534/4885GNAI1 377/4885 |
| US-20200347050-A1 | TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS | SSB, TLR8, TLR9 | GNAO1 1538/4885GNAI3 648/4885GNAI1 691/4885 |
| US-20170129876-A1 | UREA DERIVATIVES AND USES THEREOF | UACA, RB1, FLT1 | GNAO1 2556/4885GNAI3 949/4885GNAI1 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.